IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. 
A Randomised Controlled Clinical Trial in Type 2 Diabetes Comparing Semaglutide to Placebo and Liraglutide
This study has been completed.
Sponsor:
Novo Nordisk A/S
Information provided by (Responsible Party):
Novo Nordisk A/S
ClinicalTrials.gov Identifier:
NCT00696657
First received: June 11, 2008
Last updated: February 24, 2017
Last verified: February 2017
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
This trial was conducted in Europe,Asia and Africa. Study participants were randomised evenly to treatment with semaglutide (0.1 mg QW - 1.6 mg QW, 6 treatment arms, placebo or liraglutide (1.2 mg QD, or 1.8 mg QD).Treatment allocation to semaglutide or placebo was double-blind, whereas liraglutide treatment was administered open-label.Primary efficacy parameter was HbA1c and the treatment duration was 12 weeks.
| Condition | Intervention | Phase |
|---|---|---|
| Diabetes Diabetes Mellitus, Type 2 | Drug: semaglutide Drug: placebo Drug: liraglutide | Phase 2 |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Intervention Model: Parallel Assignment Masking: Participant, Investigator Primary Purpose: Treatment |
| Official Title: | Investigation of Safety and Efficacy of Five Doses of Semaglutide Versus Placebo and Open-label Liraglutide, as Add on Therapy, in Subjects Diagnosed With Type 2 Diabetes Currently Treated With Metformin or Controlled With Diet and Exercise A 12 Week Multi-centre, Multi National, Double-blind, Placebo-controlled, Randomised, Nine Armed Parallel Group, Dose Finding Trial |
Resource links provided by NLM:
Further study details as provided by Novo Nordisk A/S:
Primary Outcome Measures:
- HbA1c [ Time Frame: after 12 weeks of treatment ]
Secondary Outcome Measures:
- Percentage of subjects with an adverse events [ Time Frame: after 12 weeks of treatment ]
- Percentage of subjects with hypoglycaemic episode [ Time Frame: after 12 weeks of treatment ]
- Change from baseline in ECG [ Time Frame: week 0, week 12 ]
- Change from baseline in vital signs (Pulse) [ Time Frame: week 0, week 12 ]
- Change from baseline in vital signs (blood pressure) [ Time Frame: week 0, week 12 ]
- Change from baseline in standard safety laboratory parameters (haematology) [ Time Frame: week 0, week 12 ]
- Change from baseline in standard safety laboratory parameters ( biochemistry) [ Time Frame: week 0, week 12 ]
- Change from baseline in standard safety laboratory parameters (urinalysis) [ Time Frame: week 0, week 12 ]
- Change from baseline in calcitonin [ Time Frame: week 0, week 12 ]
- Percentage of subjects developing anti-semaglutide antibodies [ Time Frame: after 12 weeks of treatment ]
| Enrollment: | 415 |
| Actual Study Start Date: | June 3, 2008 |
| Study Completion Date: | February 5, 2009 |
| Primary Completion Date: | February 5, 2009 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
| Experimental: A |
Drug: semaglutide
0.1 mg, once weekly, s.c. injection
Other Name: NN9535
|
| Experimental: B |
Drug: semaglutide
0.2 mg, once weekly, s.c. injection
Other Name: NN9535
|
| Experimental: C |
Drug: semaglutide
0.4 mg, once weekly, s.c. injection
Other Name: NN9535
|
| Experimental: D |
Drug: semaglutide
0.8 mg, once weekly, s.c. injection
Other Name: NN9535
|
| Experimental: E |
Drug: semaglutide
0.8 mg with titration, once weekly, s.c. injection
Other Name: NN9535
|
| Experimental: F |
Drug: semaglutide
1.6 mg with titration, once weekly, s.c. injection
Other Name: NN9535
|
| Placebo Comparator: G1 |
Drug: placebo
0.1 mg, once weekly, s.c. injection
|
| Placebo Comparator: G2 |
Drug: placebo
0.2 mg, once weekly, s.c. injection
|
| Placebo Comparator: G3 |
Drug: placebo
0.4 mg, once weekly, s.c. injection
|
| Placebo Comparator: G4 |
Drug: placebo
0.8 mg with titration, once weekly, s.c. injection
|
| Placebo Comparator: G5 |
Drug: placebo
0.8 mg with titration, once weekly, s.c. injection
|
| Placebo Comparator: G6 |
Drug: placebo
1.6 mg, once weekly, s.c. injection
|
| Experimental: H |
Drug: liraglutide
1.2 mg with titration, once daily, s.c. injection
|
| Experimental: I |
Drug: liraglutide
1.8 mg with titration, once daily, s.c. injection
|
Eligibility| Ages Eligible for Study: | 18 Years and older (Adult, Senior) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | No |
Criteria
Inclusion Criteria:
- Men and women-not-of-childbearing potential diagnosed with type 2 diabetes for at least three months
- Stable treatment regimen with either metformin (at least 1500 mg) or diet and exercise alone for at least three months
- HbA1c: 7.0-10.0 % (both inclusive)
- Body weight between 60 kg and 110 kg
Exclusion Criteria:
- Treatment with insulin, GLP-1 receptor agonists (including liraglutide), dipeptidyl peptidase-4 inhibitors, sulphonylurea, thiazolidinediones, Alpha-GIs, or any investigational drug, within the last three months
- Impaired liver or kidney function
- Proliferative retinopathy or maculopathy requiring acute treatment
- Clinically significant active cardiovascular disease and uncontrolled treated/untreated hypertension
- Recurrent major hypoglycaemia or hypoglycaemic unawareness
- Present or planned use of any drug which could interfere with the glucose levels (e.g. systemic corticosteroids)
Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study.
To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below.
For general information, see Learn About Clinical Studies.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00696657
Show 77 Study Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00696657
Show 77 Study Locations
Sponsors and Collaborators
Novo Nordisk A/S
Investigators
| Study Director: | Global Clinical Registry (GCR, 1452) | Novo Nordisk A/S |
More Information
Additional Information:
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
| Responsible Party: | Novo Nordisk A/S |
| ClinicalTrials.gov Identifier: | NCT00696657 History of Changes |
| Other Study ID Numbers: |
NN9535-1821 2007-003956-12 ( EudraCT Number ) |
| Study First Received: | June 11, 2008 |
| Last Updated: | February 24, 2017 |
Additional relevant MeSH terms:
|
Diabetes Mellitus Diabetes Mellitus, Type 2 Glucose Metabolism Disorders Metabolic Diseases Endocrine System Diseases Liraglutide |
Hypoglycemic Agents Physiological Effects of Drugs Incretins Hormones Hormones, Hormone Substitutes, and Hormone Antagonists |
ClinicalTrials.gov processed this record on August 16, 2017